TNDM Share Price Performance
US$23.32
3.51 (17.72%)
19.3% undervalued intrinsic discount
US$28.91
Fair Value
Price US$23.32
AnalystConsensusTarget US$28.91
AnalystHighTarget US$49.38
AnalystLowTarget US$20.00
Fair ValueUS$28.91
Share Pricen/a
Tandem Diabetes Care, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
TNDM Community Narratives
AN
Fair Value US$28.91 19.3% undervalued intrinsic discount
TNDM: Revenue Momentum And Renewal Cycle Will Fuel Continued Upside Potential
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value US$49.38 52.8% undervalued intrinsic discount
Digital Health Integration And Global Expansion Will Elevate Diabetes Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$20 16.6% overvalued intrinsic discount
Persistent Pricing Pressure And Commoditization Will Undermine Diabetes Care Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Persistent Pricing Pressure And Commoditization Will Undermine Diabetes Care Outlook
Key Takeaways Intensifying pricing pressure, commoditization, and disruptive technologies threaten profitability, market share, and revenue growth, amplifying risks of technological obsolescence and margin compression. International expansion is challenged by regulatory and operational risks, while shifts toward value-based care reduce long-term market opportunities and earnings potential.Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
16.6% overvalued intrinsic discount
Fair Value
Profit Margin
0.38%
Future PE
381.15x
Price in 2029
US$25.13
Digital Health Integration And Global Expansion Will Elevate Diabetes Care
Key Takeaways Accelerated pharmacy channel adoption, international direct sales, and digital integration could significantly boost revenue, margins, user retention, and free cash flow ahead of expectations. Next-generation automated and tubeless products, combined with a rapidly expanding diabetes market, position Tandem for sustained growth and increased market share.Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$49.38
52.8% undervalued intrinsic discount
Fair Value
Profit Margin
4.42%
Future PE
64.34x
Price in 2029
US$62.21
TNDM: Revenue Momentum And Renewal Cycle Will Fuel Continued Upside Potential
Key Takeaways Expanding pharmacy channels, international sales, and innovative products are driving higher-margin recurring revenues, topline growth, and improved earnings. Increased market penetration through MDI conversions, type two diabetes adoption, and technology integration is expanding the addressable market and reinforcing ecosystem lock-in.Read more
188
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$28.91
19.3% undervalued intrinsic discount
Fair Value
Profit Margin
3.06%
Future PE
64.5x
Price in 2029
US$36.3
Trending Discussion
Recently Updated Narratives
AN
TNDM: Pharmacy And PayGo Transition Will Sustain Overvaluation Risk Beyond 2026
Fair Value: US$20 16.6% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TNDM: Pharmacy And PayGo Transition Will Drive More Predictable Cash Flow
Fair Value: US$49.38 52.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TNDM: PayGo Pharmacy Transition Will Shape Predictable Margins And Execution Risks
Fair Value: US$28.91 19.3% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Tandem Diabetes Care, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.00
- 53.81%
- -20.17%
- 203.0%
About TNDM
- Founded
- 2006
- Employees
- 2500
- CEO
- WebsiteView website
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
